This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 Mar;56(3):257-9.

doi: 10.1002/jcph.599. Epub 2015 Sep 18.

A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

Charles Oo¹, Lorraine M Rusch²

Affiliations

PMID: 26211513
DOI: 10.1002/jcph.599

A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

Charles Oo et al. J Clin Pharmacol. 2016 Mar.

. 2016 Mar;56(3):257-9.

doi: 10.1002/jcph.599. Epub 2015 Sep 18.

Authors

Charles Oo¹, Lorraine M Rusch²

Affiliations

¹ Morris Plains, NJ, USA.
² Vince & Associates Clinical Research, Inc., Overland Park, KS, USA.

PMID: 26211513
DOI: 10.1002/jcph.599

No abstract available

PubMed Disclaimer

Similar articles

Orphanage at the FDA.
Chen E. Chen E. J Cardiovasc Transl Res. 2012 Oct;5(5):735-6. doi: 10.1007/s12265-010-9242-2. Epub 2010 Nov 16. J Cardiovasc Transl Res. 2012. PMID: 21080134 No abstract available.
Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E. Tambuyzer E. Nat Rev Drug Discov. 2010 Dec;9(12):921-9. doi: 10.1038/nrd3275. Epub 2010 Nov 9. Nat Rev Drug Discov. 2010. PMID: 21060315 Review.
Regulators adopt more orphan drugs.
Reardon S. Reardon S. Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a. Nature. 2014. PMID: 24695293 No abstract available.
The Orphan Drug Act Revisited.
Thomas S, Caplan A. Thomas S, et al. JAMA. 2019 Mar 5;321(9):833-834. doi: 10.1001/jama.2019.0290. JAMA. 2019. PMID: 30768155 No abstract available.
The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA, Freeman SN, Imoisili MA, Coté TR. Burke KA, et al. Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193. Clin Pharmacol Ther. 2010. PMID: 20856241 Review.

See all similar articles

Cited by

Making Sure That Orphan Incentives Tip the Right Way in Europe.
Horgan D, Koeva-Balabanova J, Capoluongo E, Jagielska B, Cattaneo I, Kozaric M, Tumiene B, El Ahl JP, Lal JA, Kalra D, Malats N. Horgan D, et al. Healthcare (Basel). 2022 Aug 23;10(9):1600. doi: 10.3390/healthcare10091600. Healthcare (Basel). 2022. PMID: 36141212 Free PMC article.
Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum.
Walburn J, Canfield M, Norton S, Sainsbury K, Araújo-Soares V, Foster L, Berneburg M, Sarasin A, Morrison-Bowen N, Sniehotta FF, Sarkany R, Weinman J. Walburn J, et al. Br J Health Psychol. 2019 Sep;24(3):668-686. doi: 10.1111/bjhp.12375. Epub 2019 Jun 10. Br J Health Psychol. 2019. PMID: 31183946 Free PMC article.
Hybrid Materials Based on Magnetic Iron Oxides with Benzothiazole Derivatives: A Plausible Potential Spectroscopy Probe.
Corrêa S, Rosa IA, Andolpho GA, Assis LC, Pires MDS, Lacerda LCT, Nogueira FGE, Cunha EFFD, Nepovimova E, Kuca K, Ramalho TC. Corrêa S, et al. Int J Mol Sci. 2021 Apr 12;22(8):3980. doi: 10.3390/ijms22083980. Int J Mol Sci. 2021. PMID: 33921510 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information